Lv1
70 积分 2022-09-22 加入
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
1个月前
已完结
Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China)
1个月前
已完结
Changes in insulin utilization in China from 2020 to 2022
1个月前
已完结
IcoSema and the evolution of fixed-ratio insulin–GLP-1 receptor agonist therapies
1个月前
已完结
A 0.9 pJ/Bit 56Gb/s High-Swing Tri-Mode Wireline Transmitter with 6-Bit DAC Controlled Tailless-CML Driver and Impedance Calibration Loop
2个月前
已完结
IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
4个月前
已关闭
糖尿病肾脏病早期筛查与管理专家共识（2025版）
5个月前
已完结
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group
6个月前
已关闭
Type 2 diabetes
7个月前
已完结
皖公网安备34019202002308
